Author

Kristen E. Stevenson

Dana-Farber Cancer InstituteORCID 0000-0002-0647-1431Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Approach:statistical model· 2 Approach:benchmark study· 1 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

Agnes J. VialeiD· 1 shared Akifumi Takaori‐KondoiD· 1 shared Alan DenAdeliD· 1 shared Alejandro J. Gupta· 1 shared Alex K. ShalekiD· 1 shared Alexandra G. SmithiD· 1 shared Alexandria Van ScoykiD· 1 shared Andrea PellagattiiD· 1 shared

Activity by Year

2020-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Agnes J. VialeORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintJun 6, 2024

Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease

Peter S. Winter, Michelle L. Ramseier, Andrew W. Navia…·Mark Alan Murakami

This study identifies mutation and transcriptional state compatibility in Ph+ ALL MRD, showing that targeting these interactions can overcome BCR::ABL1 independence and improve MRD monitoring.

3 citations

humanbulk RNA-seq

𝕏 PostBluesky

GenomicsNature MedicinePeer-reviewedAug 3, 2020

Implications of TP53 Allelic State for Genome Stability, Clinical Presentation and Outcomes in Myelodysplastic Syndromes

Elsa Bernard, Yasuhito Nannya, Robert Paul Hasserjian…·Elli Papaemmanuil

The paper examines TP53 allelic states in MDS patients, finding that bi-allelic targeting is linked to worse outcomes, while mono-allelic targeting does not differ from wild-type patients.

648 citationstop 1%

humanDNA methylation

𝕏 PostBluesky